Chadds Ford, PA, United States of America

Yun-Long Li

Average Co-Inventor Count = 4.1

ph-index = 22

Forward Citations = 1,619(Granted Patents)

Forward Citations (Not Self Cited) = 888(Sep 21, 2024)

DiyaCoin DiyaCoin 2.08 

Inventors with similar research interests:


Location History:

  • Newark, DE (US) (2011)
  • Wilmington, DE (US) (2005 - 2014)
  • Chadds Ford, DE (US) (2015)
  • Late of Chadds Ford, PA (US) (2017)
  • Chadds Ford, PA (US) (2010 - 2024)


Years Active: 2005-2025

where 'Filed Patents' based on already Granted Patents

95 patents (USPTO):
14 patents (CIPO):

Title: Inventor Spotlight: Yun-Long Li - Innovating in the Field of JAK Inhibitors

Introduction: Yun-Long Li, a prolific inventor hailing from Chadds Ford, PA, has made significant contributions in the realm of pharmaceuticals with a focus on Janus kinase (JAK) inhibitors. With an impressive portfolio of 90 patents to his name, Li's innovative spirit and dedication to improving healthcare have not gone unnoticed.

Latest Patents: Among Li's latest patents are groundbreaking inventions such as "Bipyrazole derivatives as JAK inhibitors" and "Tricyclic fused thiophene derivatives as JAK inhibitors." These compounds and their pharmaceutical formulations showcase Li's expertise in developing novel therapies for a range of conditions including inflammatory disorders, autoimmune diseases, cancer, and more.

Career Highlights: Throughout his career, Yun-Long Li has made significant strides in the pharmaceutical industry, notably working with esteemed companies like Incyte Corporation and Incyte Holdings Corporation. His contributions have not only expanded the intellectual property landscape but have also paved the way for new treatment modalities in the field of JAK inhibition.

Collaborations: In his professional journey, Li has had the privilege of collaborating with talented individuals such as Song Mei and Andrew Paul Combs. These partnerships have synergized innovative ideas, fostered creativity, and propelled Li's research endeavors forward to greater heights.

Conclusion: In conclusion, Yun-Long Li stands as a beacon of innovation in the realm of pharmaceuticals, particularly in the development of JAK inhibitors. His extensive patent portfolio, coupled with his collaborative spirit and industry experience, cements his legacy as a pioneering inventor shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…